Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress

Antioxidants and Redox Signaling

Volumn 18, Issue 12, 2013, Pages 1418-1427

  Radermacher, Kim A ^a,b   Wingler, Kirstin ^a,b,c   Langhauser, Friederike ^d   Altenhöfer, Sebastian ^a,b   Kleikers, Pamela ^a   Hermans, J J Rob ^a,b   Hrabě De Angelis, Martin ^e,f   Kleinschnitz, Christoph ^d   Schmidt, Harald H H W ^a,b,c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; APOCYNIN; ENZYME INHIBITOR; FIBRINOLYTIC AGENT; GKT 136901; HYDROGEN PEROXIDE; PEPTIDE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE INHIBITOR; UNCLASSIFIED DRUG; VAS 2870; VAS 3947;

ANTIOXIDANT ACTIVITY; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SOLUBILITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; EXPERIMENTAL MODEL; HUMAN; KNOCKOUT MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; BRAIN INFARCTION; BRAIN ISCHEMIA; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GENE KNOCKOUT TECHNIQUES; HUMANS; NADPH OXIDASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RESEARCH DESIGN;

EID: 84875181886     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4797     Document Type: Review

References (72)

1. Ago T, Kitazono T, Kuroda J, Kumai Y, Kamouchi M, Ooboshi H, Wakisaka M, Kawahara T, Rokutan K, Ibayashi S, and Iida M. NAD(P)H oxidases in rat basilar arterial endothelial cells. Stroke 36: 1040-1046, 2005..
2. Aldieri E, Riganti C, Polimeni M, Gazzano E, Lussiana C, Campia I, and Ghigo D. Classical inhibitors of NOX NAD(P)H oxidases are not specific. Curr Drug Metab 9: 686-696, 2008..
3. Altenhofer S, Kleikers PW, Radermacher KA, Scheurer P, Rob Hermans JJ, Schiffers P, Ho H, Wingler K, and Schmidt HH. The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cell Mol Life Sci 69: 2327-2343, 2012..
4. Anilkumar N, Weber R, Zhang M, Brewer A, and Shah AM. Nox4 and nox2 NADPH oxidases mediate distinct cellular redox signaling responses to agonist stimulation. Arterioscler Thromb Vasc Biol 28: 1347-1354, 2008..
5. Arimura K, Ago T, Kuroda J, Ishitsuka K, Nishimura A, Sugimori H, Kamouchi M, Sasaki T, and Kitazono T. Role of NADPH oxidase 4 in Brain Endothelial cells after Ischemic Stroke. Stroke 43: A2514, 2012..
6. Bedard K and Krause KH. The NOX family of ROSgenerating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313, 2007..
7. Ben Mkaddem S, Pedruzzi E, Werts C, Coant N, Bens M, Cluzeaud F, Goujon JM, Ogier-Denis E, and Vandewalle A. Heat shock protein gp96 and NAD(P)H oxidase 4 play key roles in Toll-like receptor 4-activated apoptosis during renal ischemia/reperfusion injury. Cell Death Differ 17: 1474-1485, 2010..
8. Brait VH, Jackman KA, Walduck AK, Selemidis S, Diep H, Mast AE, Guida E, Broughton BR, Drummond GR, and Sobey CG. Mechanisms contributing to cerebral infarct size after stroke: gender, reperfusion, T lymphocytes, and Nox2-derived superoxide. J Cereb Blood Flow Metab 30: 1306-1317, 2010..
9. Carnesecchi S, Deffert C, Donati Y, Basset O, Hinz B, Preynat-Seauve O, Guichard C, Arbiser JL, Banfi B, Pache JC, Barazzone-Argiroffo C, and Krause KH. A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxid Redox Signal 15: 607-619, 2011..
10. Chan PH. Role of oxidants in ischemic brain damage. Stroke 27: 1124-1129, 1996..
11. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 21: 2-14, 2001..
12. Chen H, Kim GS, Okami N, Narasimhan P, and Chan PH. NADPH oxidase is involved in post-ischemic brain inflammation. Neurobiol Dis 42: 341-348, 2011..
13. Chen H, Song YS, and Chan PH. Inhibition of NADPH oxidase is neuroprotective after ischemia-reperfusion. J Cereb Blood Flow Metab 29: 1262-1272, 2009..
14. Den Hertog HM, van der Worp HB, Tseng MC, and Dippel DW. Cooling therapy for acute stroke. Cochrane Database Syst Rev: CD001247, 2009..
15. Diener HC, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Shuaib A, Ashwood T, Wasiewski W, Alderfer V, Hardemark HG, and Rodichok L. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 39: 1751-1758, 2008..
16. Dirnagl U and Fisher M. International, multicenter randomized preclinical trials in translational stroke research: It's time to act. J Cereb Blood Flow Metab 32: 933-935, 2012..
17. Dirnagl U and Fisher M. REPRINT: international, multicenter randomized preclinical trials in translational stroke research: it is time to act. Stroke 43: 1453-1454, 2012..
18. Eisener-Dorman AF, Lawrence DA, and Bolivar VJ. Cautionary insights on knockout mouse studies: the gene or not the gene? Brain Behav Immun 23: 318-324, 2009..
19. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, and Lo EH. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40: 2244-2250, 2009..
20. Flamm ES, Demopoulos HB, Seligman ML, Poser RG, and Ransohoff J. Free radicals in cerebral ischemia. Stroke 9: 445-447, 1978..
21. Gatto GJ, Ao Z, KearseMG, Zhou M, Morales CR, Daniels E, Bradley BT, Goserud MT, Goodman KB, Douglas SA, Harpel MR, and Johns DG. NADPH oxidase-dependent and -independent mechanisms of reported inhibitors of reactive oxygen generation. J Enzyme Inhibit Med Chem 2011 [Epub ahead of print]; DOI:10.3109/14756366.2011. 636360..
22. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, Hinchey JA, Howard VJ, Jauch EC, Levine SR, Meschia JF, Moore WS, Nixon JV, and Pearson TA. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42: 517-584, 2011..
23. Green SP, Cairns B, Rae J, Errett-Baroncini C, Hongo JA, Erickson RW, and Curnutte JT. Induction of gp91-phox, a component of the phagocyte NADPH oxidase, in microglial cells during central nervous system inflammation. J Cereb Blood Flow Metab 21: 374-384, 2001..
24. Halliwell B. Phagocyte-derived reactive species: salvation or suicide? Trends Biochem Sci 31: 509-515, 2006..
25. Heumuller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schroder K, and Brandes RP. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 51: 211-217, 2008..
26. Howells DW, Porritt MJ, Rewell SS, O'Collins V, Sena ES, van der Worp HB, Traystman RJ, and Macleod MR. Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J Cereb Blood Flow Metab 30: 1412-1431, 2010..
27. Hultqvist M, Olsson LM, Gelderman KA, and Holmdahl R. The protective role of ROS in autoimmune disease. Trends Immunol 30: 201-208, 2009..
28. Infanger DW, Sharma RV, and Davisson RL. NADPH oxidases of the brain: distribution, regulation, and function. Antioxid Redox Signal 8: 1583-1596, 2006..
29. Jackman KA, Miller AA, De Silva TM, Crack PJ, Drummond GR, and Sobey CG. Reduction of cerebral infarct volume by apocynin requires pretreatment and is absent in Nox2-deficient mice. Br J Pharmacol 156: 680-688, 2009..
30. Jackman KA, Miller AA, Drummond GR, and Sobey CG. Importance of NOX1 for angiotensin II-induced cerebrovascular superoxide production and cortical infarct volume following ischemic stroke. Brain Res 1286: 215-220, 2009..
31. Kahles T, Kohnen A, Heumueller S, Rappert A, Bechmann I, Liebner S, Wittko IM, Neumann-Haefelin T, Steinmetz H, Schroeder K, and Brandes RP. NADPH oxidase Nox1 contributes to ischemic injury in experimental stroke in mice. Neurobiol Dis 40: 185-192, 2010..
32. Kahles T, Luedike P, Endres M, Galla HJ, Steinmetz H, Busse R, Neumann-Haefelin T, and Brandes RP. NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke 38: 3000-3006, 2007..
33. Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, Barit D, Schwarz T, Geis C, Kraft P, Barthel K, Schuhmann MK, Herrmann AM, Meuth SG, Stoll G, Meurer S, Schrewe A, Becker L, Gailus-Durner V, Fuchs H, Klopstock T, de Angelis MH, Jandeleit-Dahm K, Shah AM, Weissmann N, and Schmidt HH. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 8: e1000479, 2010..
34. Kunz A, Anrather J, Zhou P, Orio M, and Iadecola C. Cyclooxygenase-2 does not contribute to postischemic production of reactive oxygen species. J Cereb Blood Flow Metab 27: 545-551, 2007..
35. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, and Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A 107: 15565-15570, 2010..
36. Laleu B, Gaggini F, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, Gradia A, Duboux G, Merlot C, Heitz F, Szyndralewiez C, and Page P. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 53: 7715-7730, 2010..
37. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, and Wasiewski WW. NXY-059 for acute ischemic stroke. N Engl J Med 354: 588-600, 2006..
38. Levy DE, del Zoppo GJ, Demaerschalk BM, Demchuk AM, Diener HC, Howard G, Kaste M, Pancioli AM, Ringelstein EB, Spatareanu C, and Wasiewski WW. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke 40: 3796-3803, 2009..
39. Loukogeorgakis SP, van den Berg MJ, Sofat R, Nitsch D, Charakida M, Haiyee B, de Groot E, MacAllister RJ, Kuijpers TW, and Deanfield JE. Role of NADPH oxidase in endothelial ischemia/reperfusion injury in humans. Circulation 121: 2310-2316, 2010..
40. Lu Q, Xia N, Xu H, Guo L, Wenzel P, Daiber A, Munzel T, Forstermann U, and Li H. Betulinic acid protects against cerebral ischemia-reperfusion injury in mice by reducing oxidative and nitrosative stress. Nitric Oxide Biol Chem 24: 132-138, 2011..
41. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, and Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 18: 69-82, 2006..
42. Miller AA, Drummond GR, Schmidt HH, and Sobey CG. NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. Circ Res 97: 1055-1062, 2005..
43. Nagel S, Genius J, Heiland S, Horstmann S, Gardner H, and Wagner S. Diphenyleneiodonium and dimethylsulfoxide for treatment of reperfusion injury in cerebral ischemia of the rat. Brain Res 1132: 210-217, 2007..
44. O'Collins VE, Donnan GA, and Howells DW. History of animal models of stroke. Stroke 6: 77-78, 2011..
45. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, and Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol 59: 467-477, 2006..
46. Opitz N, Drummond GR, Selemidis S, Meurer S, and Schmidt HH. The 'A's and 'O's of NADPH oxidase regulation: a commentary on "Subcellular localization and function of alternatively spliced Noxo1 isoforms". Free Radic Biol Med 42: 175-179, 2007..
47. Pollock JD, Williams DA, Gifford MA, Li LL, Du X, Fisherman J, Orkin SH, Doerschuk CM, and Dinauer MC. Mouse model of X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. Nat Genet 9: 202-209, 1995..
48. Rada B and Leto TL. Oxidative innate immune defenses by Nox/Duox family NADPH oxidases. Contrib Microbiol 15: 164-187, 2008..
49. Radermacher KA, Wingler K, Kleikers PW, Altenhofer SA, Hermans JR, Kleinschnitz C, and Schmidt HH. The 1027th target candidate in stroke: Will NADPH oxidase hold up? Exp Transl Stroke Med 4: 11, 2012..
50. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, and Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res 89: 408-414, 2001..
51. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, and Turner MB. Heart disease and stroke statistics-2012 update: a report from the american heart association. Circulation 125: e2-e220, 2012..
52. Schluter T, Steinbach AC, Steffen A, Rettig R, and Grisk O. Apocynin-induced vasodilation involves Rho kinase inhibition but not NADPH oxidase inhibition. Cardiovasc Res 80: 271-279, 2008..
53. Schroder K, Wandzioch K, Helmcke I, and Brandes RP. Nox4 acts as a switch between differentiation and proliferation in preadipocytes. Arterioscler Thromb Vasc Biol 29: 239-245, 2009..
54. Sena E, van der Worp HB, Howells D, and Macleod M. How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci 30: 433-439, 2007..
55. Sena ES, van der Worp HB, Bath PM, Howells DW, and Macleod MR. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol 8: e1000344, 2010..
56. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, and Emeribe U. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 357: 562-571, 2007..
57. Simonyi A, Serfozo P, Lehmidi TM, Cui J, Gu Z, Lubahn DB, Sun AY, and Sun GY. The neuroprotective effects of apocynin. Front Biosci 4: 2183-2193, 2012..
58. Sirker A, Zhang M, and Shah AM. NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies. Basic Res Cardiol 106: 735-747, 2011..
59. Sorce S and Krause KH. NOX enzymes in the central nervous system: from signaling to disease. Antioxid Redox Signal 11: 2481-2504, 2009..
60. STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30: 2752-2758, 1999..
61. Sun QA, Hess DT, Wang B, Miyagi M, and Stamler JS. Offtarget thiol alkylation by the NADPH oxidase inhibitor 3-benzyl-7-(2-benzoxazolyl)thio-1,2,3- triazolo[4,5-d]pyrimidine (VAS2870). Free Radic Biol Med 52: 1897-1902, 2012..
62. Tang XN, Cairns B, Cairns N, and Yenari MA. Apocynin improves outcome in experimental stroke with a narrow dose range. Neuroscience 154: 556-562, 2008..
63. Tang XN, Zheng Z, Giffard RG, and Yenari MA. Significance of marrow-derived nicotinamide adenine dinucleotide phosphate oxidase in experimental ischemic stroke. Ann Neurol 70: 606-615, 2011..
64. ten Freyhaus H, Huntgeburth M, Wingler K, Schnitker J, Baumer AT, Vantler M, Bekhite MM, Wartenberg M, Sauer H, and Rosenkranz S. Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res 71: 331-341, 2006..
65. Vallet P, Charnay Y, Steger K, Ogier-Denis E, Kovari E, Herrmann F, Michel JP, and Szanto I. Neuronal expression of the NADPH oxidase NOX4, and its regulation in mouse experimental brain ischemia. Neuroscience 132: 233-238, 2005..
66. Walder CE, Green SP, Darbonne WC, Mathias J, Rae J, Dinauer MC, Curnutte JT, and Thomas GR. Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidase. Stroke 28: 2252-2258, 1997..
67. Wang Q, Tompkins KD, Simonyi A, Korthuis RJ, Sun AY, and Sun GY. Apocynin protects against global cerebral ischemia-reperfusion-induced oxidative stress and injury in the gerbil hippocampus. Brain Res 1090: 182-189, 2006..
68. Warner DS, Sheng H, and Batinic-Haberle I. Oxidants, antioxidants and the ischemic brain. J Exp Biol 207: 3221-3231, 2004..
69. Wind S, Beuerlein K, Eucker T, Muller H, Scheurer P, Armitage ME, Ho H, Schmidt HH, and Wingler K. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol 161: 885-898, 2010..
70. Wingler K, Altenhoefer SA, Kleikers PW, Radermacher KA, Kleinschnitz C, and Schmidt HH. VAS2870 is a pan-NADPH oxidase inhibitor. Cell Mol Life Sci 69: 3159-3160, 2012..
71. Wingler K, Hermans J, Schiffers P, Moens A, Paul M, and Schmidt H. NOX 1, 2, 4, 5: Counting out oxidative stress. Br J Pharmacol 164: 866-883, 2011..
72. Zhang M, Brewer AC, Schroder K, Santos CX, Grieve DJ, Wang M, Anilkumar N, Yu B, Dong X, Walker SJ, Brandes RP, and Shah AM. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci U S A 107: 18121-18126, 2010..